Unless you’re dealing with a meme stock, “big cash,” “partnerships,” or “buyouts” would all depend on the strength of the science.
Clinical data, peer review, and regulators are the sources that we need to consider when speculating about the prospects for further industry buy-in, additional collaborations, or partnerships—not inane message board postings and rumors. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175186684